|
AMGEN, INC.
Patient Assistance Program
Patient assistance programs (PAPs) are programs created by drug companies,
such as AMGEN, INC., to offer free or low cost drugs to individuals who are unable to
pay for their medication. These Programs may also be called indigent drug programs,
charitable drug programs or medication assistance programs. Most of the best known and
most prescribed drugs can be found in these programs. All of the major drug companies
have patient assistance programs, although every company has different eligibility and
application requirements.
The AMGEN, INC. patient assistance program offers free medication to people
who otherwise cannot afford their medications. Patients must meet financial and other
program specific criteria to be eligible for assistance.
To find out how to apply for medication assistance from the AMGEN, INC. patient
assistance program, visit our Patient Center and use our Database to search for the medication needed.
For a complete listing of AMGEN, INC. medications available through
their patient assistance programs, see below:
Amgen Safety Net Foundation
|
| |
The medications available through this program are:
|
| |
|
| |
| Aranesp
(darbepoetin alfa) |
|
| |
|
| |
|
| |
|
| |
|
| |
| Imdelltra
(tarlatamab-dlle) |
|
| |
| Imlygic
(talimogene laherparepvec) |
|
| |
| Kyprolis Injection
(carfilzomib) |
|
| |
|
| |
|
| |
| Otezla Tablet
(apremilast) |
|
| |
|
| |
|
| |
|
| |
| Tezspire
(tezepelumab-ekko injection; subcutaneous) |
|
| |
|
| |
|
|
|
Amgen SupportPlus Co-Pay Program
|
| |
The medications available through this program are:
|
| |
| Avsola injection
(infliximab-axxq) |
|
| |
|
| |
|
| |
| Imdelltra
(tarlatamab-dlle) |
|
| |
| Kanjiniti
(trastuzumab-anns) |
|
| |
| Kyprolis Injection
(carfilzomib) |
|
| |
|
| |
|
| |
| Neulasta Onpro
(pegfilgrastim) |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
| talimogene laherparepvec
Imlygic |
|
| |
| infliximab-axxq injection; iv
Riabni |
|
|
|
Tavneos Connect
|
| |
The medications available through this program are:
|
| |
|
|
|
|
